北京若生智能科技有限公司
Drug Database
CO

COVID-19 vaccine (S 268019 / S268019 / Covgoze)

✓ Approved

Shionogi · 重组蛋白 · 重组蛋白

什么是 COVID-19 vaccine？

COVID-19 vaccine 是一种重组蛋白，由Shionogi研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名S 268019, S268019, Covgoze
公司Shionogi
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Shionogi

治疗适应症

COVID-19 vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsCOVID-19✓ Approved

相关研究文献

PubMedFrontiers in public health2026-09-10

Managing an infodemic in the global south: a systematic evidence synthesis from COVID-19 social listening reports.

Combrink H M V E HMVE, Mkungeka P P, Bhengu C C, Katarya R R et al.

The COVID-19 pandemic was accompanied by a widespread infodemic characterised by rapidly evolving information, misinformation, and uncertainty, particularly within low- and middle-income country contexts. Social listening emerged as a critical tool for risk communication and community engagement by enabling real-time monitoring of public concerns, misinformation, and information gaps. This study presents a systematic evidence synthesis of national COVID-19 social listening reports produced in South Africa between 2021 and 2023 to inform infodemic management in the Global South. A total of 91 publicly available social listening reports were identified through coordinated national repositories and screened according to predefined inclusion and exclusion criteria. Following PRISMA 2020 guidance for transparent reporting, misinformation signals and corresponding recommended actions were extracted, thematically coded, and synthesised. The synthesis identified 964 instances of misinformation across 12 thematic categories, with dominant themes relating to COVID-19 disease management, vaccine safety, side effects, and conspiracy narratives. In parallel, 573 recommended action items were consolidated into eight thematic response domains, emphasising community-based engagement, targeted health education, communication strategy development, political and public figure credibility, and continuous monitoring and research. Building on these findings, the study proposes a circular social listening health priority nexus that operationalises the translation of misinformation signals into adaptive public health communication responses. While this synthesis does not evaluate the effectiveness of implemented interventions, it provides structured evidence to support decision-making and priority setting for infodemic management. The findings highlight the importance of context-sensitive, adaptive communication strategies and sustained social listening systems to strengthen public health responses to future infodemics in the Global South.

PMID 42718950
阅读全文 →
PubMedExpert review of vaccines2026-09-10

Evolution of the global emergency vaccine stockpile system.

Walldorf Jenny A JA, Patel Jaymin C JC, Cibrelus Laurence L, Fernandez Katya K et al.

The emergence of epidemic-prone diseases continues to pose a threat to global health. Vaccine stockpiles allow effective and timely response to outbreaks. Global stockpiles have been established for multiple vaccines, but stockpile management has evolved in recent years, both in the number of globally managed stockpiles and in stockpile strategy, from a reactive to a more integrated approach bridging with preventive strategies. We conducted a review of published and gray literature to provide an update on the evolution of stockpile management in recent years (2014-2025), specifically for cholera, yellow fever, polio, meningococcus, COVID-19, Ebola, and mpox. The benefit of accelerated development of new vaccines and medical countermeasures to fight epidemic-prone diseases cannot be achieved without efficient and transparent stockpile management and distribution mechanisms, to ensure equitable and needs-based allocation.

PMID 42717903
阅读全文 →
PubMedBMC medical informatics and decision making2026-09-10

Machine learning-assisted mRNA vaccine pharmacovigilance: a systematic review of multi-source real-world data.

He YuLong Y, Mao Yan Y, Wang XinYu X

The rapid deployment of mRNA vaccines during the COVID-19 pandemic exposed limitations in traditional pharmacovigilance systems, including delayed reporting, high underreporting rates, and inability to calculate true incidence. Machine learning (ML) offers new pathways to overcome these challenges by integrating multi-source real-world data. We systematically reviewed English-language studies from database inception to June 2026. Searches were performed in PubMed, Embase, and Web of Science. Two reviewers independently screened records. Given substantial heterogeneity across ML tasks (signal detection, text extraction, risk prediction, prognosis stratification), algorithms, data sources, and metrics, we performed narrative synthesis. Risk of bias was assessed using adapted QUADAS-2. We identified 43 studies. For adverse-event prediction, tree-based models reported AUCs of 0.85-0.87, though estimates derive from heterogeneous settings. NLP reduced redundant signals by 17% in vaccine reporting systems. For myocarditis, ML models reached AUCs up to 0.899 in cardiovascular cohorts, but direct mRNA vaccine applications remain limited and retrospective. Emerging platforms (self-amplifying and tumor mRNA vaccines) lack post-marketing data, rendering ML applications largely conceptual. ML-assisted pharmacovigilance enables a shift from passive to active, intelligent monitoring. Despite challenges in data quality, model interpretability, and regulatory approval, intelligent pharmacovigilance systems will become essential infrastructure for safeguarding public health.

PMID 42717339
阅读全文 →
PubMedThe Pediatric infectious disease journal2026-09-10

SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.

Di Chiara Costanza C, Farrar Daniel S DS, Bettinger Julie A JA, Campigotto Aaron A et al.

Co-circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with other respiratory viruses raised concerns that coinfections may increase pediatric coronavirus disease 2019 (COVID-19) severity, but evidence is limited by variable testing practices. We assessed the epidemiology and outcomes of SARS-CoV-2 respiratory viral coinfections in hospitalized children. We analyzed national surveillance data from the Canadian Immunization Monitoring Program, ACTive (IMPACT) COVID-19 study. Children aged <17 years hospitalized with confirmed COVID-19 during Delta and Omicron periods were included. Coinfection was defined as SARS-CoV-2 plus ≥1 additional respiratory virus. Primary analyses were restricted to centres with systematic multiplex polymerase chain reaction (PCR) testing of all admissions with acute respiratory illness (n = 5), while secondary analyses included all centres (n = 13). Associations with outcomes (respiratory support, ventilation, intensive care and severe COVID-19) were estimated using multivariable mixed-effects logistic regression and adjusted odds ratios (aORs). Among 2831 hospitalized children, 938 were admitted at centers with systematic multiplex PCR testing, among whom 18.6% had ≥1 respiratory viral coinfection. Respiratory syncytial virus (39.7%) and enterovirus/rhinovirus (38.5%) coinfections were the most common. Coinfections were not associated with increased odds of severe COVID-19 in centers with systematic multiplex PCR testing (aOR 0.94; 95% confidence interval, 0.76-1.15). In secondary analyses including all centers irrespective of testing strategy, coinfections were associated with increased odds of severe COVID-19 (aOR 1.42; 95% confidence interval, 1.05-1.91). In centers that systematically conducted multiplex PCR testing, SARS-CoV-2 respiratory viral coinfections were not associated with increased COVID-19 severity. Differences observed when including centers without systematic testing underscore the importance of considering testing strategies when evaluating the clinical impact of coinfections.

PMID 42717388
阅读全文 →
PubMedGinekologia polska2026-09-10

COVID-19 and pregnancy: is a "forgotten" disease still a threat?

Januszewski Marcin M, Ziuzia-Januszewska Laura L, Jakimiuk Artur J AJ

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly affected global health, including maternal and perinatal outcomes. Although the acute phase of the pandemic has subsided, the continued emergence of new viral variants, waning population immunity, and suboptimal vaccination coverage among women of reproductive age suggest that COVID-19 in pregnancy may remain a clinically relevant problem. This review summarizes current evidence regarding the clinical course, complications, and prevention of SARS-CoV-2 infection during pregnancy, addressing whether COVID-19 should be considered a "forgotten" obstetric disease. Most pregnant women develop asymptomatic or mild infection; however, pregnancy is associated with an increased risk of severe disease, intensive care unit admission, mechanical ventilation, and maternal mortality, particularly among women of advanced maternal age, with obesity, comorbidities, or without vaccination. SARS-CoV-2 infection during pregnancy is consistently linked with a higher incidence of preeclampsia, including severe forms such as eclampsia and HELLP syndrome, increased rates of cesarean delivery and, in many populations, preterm birth. Vertical transmission is uncommon but documented. Severe placental involvement, referred to as COVID-19 placentitis, may result in placental insufficiency, fetal hypoxia, and stillbirth. Expression of angiotensin-converting enzyme 2 within the placenta provides a biological basis for viral tropism and potential disruption of placental defense mechanisms, contributing to adverse perinatal outcomes. COVID-19 vaccination before conception, during pregnancy, and throughout breastfeeding is safe and effective. Immunization significantly reduces the risk of severe maternal disease, preterm birth, emergency cesarean delivery, stillbirth, and neonatal hospitalization, while also conferring passive protection to infants. Maintaining up-to-date vaccination remains essential for preventing maternal and perinatal complications associated with SARS-CoV-2 infection.

PMID 42720199
阅读全文 →
PubMedJournal of medical virology2026-09-10

Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.

Sreelakshmi P R PR, Wagh Priyanka P, Sarje Prakash P, Shinde Tanvi T et al.

High prevalence of post-acute sequelae of COVID-19 (PASC/long COVID) has led to the determination of the pathophysiology of PASC. In a hospital-based cross-sectional survey, we assessed the clinical and immunological parameters in a set of 67 PASC and 81 recovered individuals from COVID-19 (N-PASC), to identify the immune biomarkers associated with the mechanistic cornerstone of this condition. PASC had higher chronic comorbidities, hospitalization, and ICU admissions during the COVID-19 pandemic compared to the N-PASC group. Though comparable SARS-CoV-2-specific antibodies were detected across the groups, their functionality (NAbs) was significantly higher in the N-PASC. PASC patients exhibited features of immune dysregulation, characterized by altered coordination between cellular and humoral immune responses despite broadly comparable cytokine profiles and T-cell responses. ROC analysis in hospitalized PASC and hospitalized N-PASC subjects sampled at 1, 2, and 3 years post COVID-19 supported the utility of IL-6 as a biomarker for long-term inflammatory activity. Higher FGF-basic levels in the hospitalized PASC compared to non-hospitalized PASC highlighted a potential association between elevated growth factor signaling and severity-related immune dysregulation, tissue damage that may have utility as a biomarker candidate. Our analysis supports a dysregulated crosstalk between humoral and cellular immunity in PASC patients, which could be leading to inflammation and persistent clinical symptoms associated with this debilitating condition. In conclusion, comparable T-cell and cytokine responses among long COVID and recovered individuals suggest that persistent symptoms are unlikely to be driven by impaired antiviral immunity, underscoring the potential role of immune dysregulation.

PMID 42720191
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多COVID-19 vaccine